Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia.

M. Hoyle,Gabriel Rogers,T. Moxham,Zulian Liu,K. Stein
DOI: https://doi.org/10.1016/j.jval.2011.07.006
IF: 5.156
2011-12-01
Value in Health
Abstract:
What problem does this paper attempt to address?